Scientists found evidence that novel coronavirus infects the mouth’s cells
On Mar. 25, 2021, an international team of scientists announced they had found evidence that SARS-CoV-2 infects cells…
Biotechnology | HIV | Therapeutics | Vaccine
Oregon Health & Science University researchers unlocked HIV vaccine candidate’s mysteries 20 years later
On Mar. 25, 2021, about two decades after first devising a new kind of vaccine, Oregon Health &…
Virginia Tech and UVA virologists developed broadly protective coronavirus vaccines
On Mar. 24, 2021, Virginia Tech researchers announced that their candidate Coronavirus vaccines, prevented pigs from becoming ill…
Pfizer initiated phase 1 study of movel oral antiviral therapeutic agent against SARS-CoV-2
On Mar. 23, 2021, Pfizer announced that it was progressing to multiple ascending doses after completing the dosing…
CureVac expanded CVnCoV COVID-19 vaccine candidate clinical trial Aanalyses to include phase 2b/3 variant
On Mar. 22, 2021, CureVac announced plans to expand and further specify the protocols of its ongoing late-stage…
US, Chile and Peru interim trial data showed Oxford-AstraZeneca vaccine was safe and highly effective
On Mar. 22, 2021, Oxford University announced that a Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted…
Cepheid received Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test
On Mar. 21, 2021, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
FDA authorized first machine learning-based screening device to identify COVID-19 infection biomarkers
On Mar. 19, 2021, the FDA issued an emergency use authorization to Tiger Tech Solutions for the first…
Altasciences partnered with NRC of Canada to qualify quantitative serological assay for detection of SARS-CoV-2 IgG antibodies
On Mar. 17, 2021, Altasciences working with the National Research Council of Canada (NRC), announced that it had…
Tonix Pharma reported positive COVID-19 vaccine efficacy results in non-human primates vaccinated with TNX-1800
On Mar. 17, 2021, Tonix Pharma announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox…
ImmunityBio announced positive interim phase I safety data of hAd5 T-cell COVID-19 vaccine candidate
On Mar. 15, 2021, ImmunityBio announced it had met the safety requirements for the first 12 participants in…
ImmunityBio announced novel ACE2 decoy COVID-19 therapeutic that showed high binding to SARS-CoV-2 variants
On Mar. 11, 2021, ImmunityBio announced it was developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize…
CEPI and VBI Vaccines collaborated to advance vaccine candidates against COVID-19 variants
On Mar. 10, 2021, CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines announced a partnership to…
Innovation Pharma’s COVID-19 drug candidate Brilacidin among top three percent predicted most effective against SARS-CoV-2
On Mar. 10, 2021, Innovation Pharmaceuticals announced that a Machine Learning (Artificial Intelligence) model used to screen 1,482…
NIH scientists used human cerebral organoid to test drug for deadly brain disease
On Mar. 9, 2021, the NIH announced that approximately two years after establishing a human cerebral organoid system…
NanoViricides pan-coronavirus COVID-19 drug candidates highly effective in pre-clinical animal atudies
On Mar. 9, 2021, NanoViricides announced that NV-CoV-2 and NV-CoV-2-R were found to be highly effective against a…
VBI Vaccines announced enrollment in adaptive phase 1/2 study of prophylactic COVID-19 vaccine candidate
On Mar. 9, 2021, VBI Vaccines announced the initiation of enrollment of its Phase 1/2 clinical study of…
ImmunityBio and NantKwest began dosing participants in global trials for novel COVID-19 vaccine
On Mar. 8, 2021, ImmunityBio and NantKwest announced that the first cohorts of their South Africa and U.S….
Recruitment and enrollment began for Innovation Pharma’s phase 2 clinical trial of Brilacidin for COVID-19
On Mar. 5, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Company’s international Phase 2…
Abbott’s received FDA EUA for laboratory PCR assay that detects and differentiates SARS-CoV-2, Flu A, Flu B and RSV
On Mar. 5, 2021, Abbott announced the U.S. Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) for…
Ridgeback Biotherapeutics and Merck announced preliminary findings from phase 2a trial of investigational COVID-19 therapeutic
On Mar. 5, 2021, Merck and Ridgeback Biotherapeutics, announced preliminary results from Ridgebackﾒs Phase 2a randomized, double-blind, placebo-controlled…
FDA issued authorization for first molecular non-prescription, at-home test
On Mar. 5, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the…
New evidence COVID-19 antibodies, vaccines less effective against variants
On Mar. 4, 2021, researchers at the University School of Medicine in St. Louis announced that three new,…
Biotechnology | Disease | FDA
Luminex received FDA Emergency Use Authorization and CE Mark for expanded NxTAG panel test Including SARS-CoV-2
On Mar. 4, 2021, Luminex announced that it had received Emergency Use Authorization (EUA) from the U.S. Food…
Men, older adults and smokers more prone to infection by SARS-CoV-2
On Mar. 3, 2021, TGen, an affiliate of City of Hope announced that an in-depth analysis of the…
NIH halted trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms
On Mar. 2, 2021, the NIH halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent…
NIH launched effort to understand MIS-C, range of SARS-CoV-2 effects on children
On Mar. 2, 2021, the NIH announced that it had launched a research effort to understand how SARS-CoV-2,…
NanoViricides pan-coronavirus COVID-19 drug candidates highly effective in pre-clinical animal atudies
On Mar. 2, 2021, NanoViricides reported that NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison…
Innovation Pharma announced publication in Journal Viruses on the anti-SARS-CoV-2 properties of brilacidin
On Mar. 2, 2021, Innovation Pharmaceuticals reported that eight sites were participating in the Companyﾒs international Phase 2…
COVID-19 can kill heart muscle cells, interfere with contraction
On Mar. 1, 2021, a study from Washington University School of Medicine in St. Louis provided evidence that…